| 1. Timmerman H.. (1990) Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?, 33 (1): [PMID:1967317] [10.1021/jm00163a001] |
| 2. Sowell JW, Tang Y, Valli MJ, Chapman JM, Usher LA, Vaughan CM, Kosh JW.. (1992) Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine., 35 (6): [PMID:1552502] [10.1021/jm00084a015] |
| 3. Lombardo F, Obach RS, Shalaeva MY, Gao F.. (2004) Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics., 47 (5): [PMID:14971904] [10.1021/jm030408h] |
| 4. Santilli AA, Scotese AC, Morris RL, Schiehser GA, Teller DM, Nielsen ST, Strike DP.. (1988) Syntheses and gastric acid antisecretory properties of the H2-receptor antagonist. N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]thieno[3,4-d]isot hiazol-3-amine 1,1-dioxide and related derivatives., 31 (7): [PMID:2898534] [10.1021/jm00402a039] |
| 5. Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.. (2002) Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues., 45 (1): [PMID:11754586] [10.1021/jm010217j] |
| 6. Li L, Kracht J, Peng S, Bernhardt G, Elz S, Buschauer A.. (2003) Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine., 13 (10): [PMID:12729649] [10.1016/s0960-894x(03)00235-x] |
| 7. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 8. Sanfilippo PJ, Urbanski M, Press JB, Hajos ZG, Shriver DA, Scott CK.. (1988) Synthesis of (aryloxy)alkylamines. 1. Novel antisecretory agents with H+K+-ATPase inhibitory activity., 31 (9): [PMID:2842503] [10.1021/jm00117a018] |
| 9. Kojima K, Nakajima K, Kurata H, Tabata K, Utsui Y. (1996) Synthesis of a piperidinomethylthiophene derivative as H2-antagonist with inhibitory activity against Helicobacter pylori, 6 (15): [10.1016/0960-894X(96)00313-7] |
| 10. Lumma WC, Anderson PS, Baldwin JJ, Bolhofer WA, Habecker CN, Hirshfield JM, Pietruszkiewicz AM, Randall WC, Torchiana ML, Britcher SF, Clineschmidt BV, Denny GH, Hirschmann R, Hoffman MJ, Phillips BT, Streeter KB.. (1982) Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists., 25 (3): [PMID:6121913] [10.1021/jm00345a002] |
| 11. Lipinski CA, LaMattina JL, Oates PJ.. (1986) Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists., 29 (11): [PMID:2878075] [10.1021/jm00161a005] |
| 12. Crivori P, Cruciani G, Carrupt PA, Testa B.. (2000) Predicting blood-brain barrier permeation from three-dimensional molecular structure., 43 (11): [PMID:10841799] [10.1021/jm990968+] |
| 13. Hirschfeld J, Buschauer A, Elz S, Schunack W, Ruat M, Traiffort E, Schwartz JC.. (1992) Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor., 35 (12): [PMID:1613748] [10.1021/jm00090a013] |
| 14. Miyashita M, Matsumoto T, Matsukubo H, Iinuma F, Taga F, Sekiguchi H, Hamada K, Okamura K, Nishino K.. (1992) Synthesis and antiulcer activity of N-substituted N'-[3-[3-(piperidinomethyl)phenoxy]propyl]ureas: histamine H2-receptor antagonists with a potent mucosal protective activity., 35 (13): [PMID:1352351] [10.1021/jm00091a012] |
| 15. Lombardo F, Shalaeva MY, Tupper KA, Gao F.. (2001) ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds., 44 (15): [PMID:11448232] [10.1021/jm0100990] |
| 16. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 17. Lombardo F, Obach RS, Shalaeva MY, Gao F.. (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data., 45 (13): [PMID:12061889] [10.1021/jm0200409] |
| 18. Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H.. (2000) Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives., 43 (17): [PMID:10966750] [10.1021/jm000169n] |
| 19. Kinney WA, Lee NE, Blank RM, Demerson CA, Sarnella CS, Scherer NT, Mir GN, Borella LE, DiJoseph JF, Wells C.. (1990) N-phenyl-2-pyridinecarbothioamides as gastric mucosal protectants., 33 (1): [PMID:2296028] [10.1021/jm00163a053] |
| 20. Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL.. (2001) Cheminformatic models to predict binding affinities to human serum albumin., 44 (25): [PMID:11728183] [10.1021/jm010960b] |
| 21. Sasho S, Obase H, Ichikawa S, Kitazawa T, Nonaka H, Yoshizaki R, Ishii A, Shuto K.. (1993) Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility., 36 (5): [PMID:8496937] [10.1021/jm00057a007] |
| 22. Katsura Y, Inoue Y, Tomishi T, Ishikawa H, Takasugi H.. (1994) Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury., 37 (1): [PMID:7904648] [10.1021/jm00027a007] |
| 23. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE.. (1988) Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists., 31 (3): [PMID:2894467] [10.1021/jm00398a028] |
| 24. Wohnsland F, Faller B.. (2001) High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes., 44 (6): [PMID:11300874] [10.1021/jm001020e] |
| 25. Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M, Christensen MS.. (2005) In silico prediction of membrane permeability from calculated molecular parameters., 48 (3): [PMID:15689164] [10.1021/jm049661n] |
| 26. Ermondi G, Lorenti M, Caron G.. (2004) Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction., 47 (16): [PMID:15267234] [10.1021/jm040760a] |
| 27. Fujikawa M, Nakao K, Shimizu R, Akamatsu M.. (2007) QSAR study on permeability of hydrophobic compounds with artificial membranes., 15 (11): [PMID:17418579] [10.1016/j.bmc.2007.03.040] |
| 28. Santana L, González-Díaz H, Quezada E, Uriarte E, Yáñez M, Viña D, Orallo F.. (2008) Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors., 51 (21): [PMID:18834112] [10.1021/jm800656v] |
| 29. Wan H, Ahman M, Holmén AG.. (2009) Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs., 52 (6): [PMID:19256501] [10.1021/jm801441s] |
| 30. Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Hornéy C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.. (2007) Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase., 51 (10): [PMID:17606674] [10.1128/aac.00246-07] |
| 31. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.. (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1., 51 (19): [PMID:18788725] [10.1021/jm8003152] |
| 32. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P.. (2008) Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)., 51 (11): [PMID:18457386] [10.1021/jm7015683] |
| 33. Li H, Sun J, Sui X, Liu J, Yan Z, Liu X, Sun Y, He Z.. (2009) First-principle, structure-based prediction of hepatic metabolic clearance values in human., 44 (4): [PMID:18768239] [10.1016/j.ejmech.2008.07.027] |
| 34. Alimuddin M, Grant D, Bulloch D, Lee N, Peacock M, Dahl R.. (2008) Determination of log D via automated microfluidic liquid-liquid extraction., 51 (16): [PMID:18666772] [10.1021/jm8005228] |
| 35. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 36. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination., 53 (3): [PMID:20070106] [10.1021/jm901371v] |
| 37. Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.. (2009) Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain., 17 (19): [PMID:19734051] [10.1016/j.bmc.2009.08.022] |
| 38. Sui X, Sun J, Li H, Wang Y, Liu J, Liu X, Zhang W, Chen L, He Z.. (2009) Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data., 44 (11): [PMID:19586686] [10.1016/j.ejmech.2009.06.004] |
| 39. Avdeef A, Tam KY.. (2010) How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?, 53 (9): [PMID:20373811] [10.1021/jm901846t] |
| 40. Mahindroo N, Connelly MC, Punchihewa C, Yang L, Yan B, Fujii N.. (2010) Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway., 18 (13): [PMID:20605720] [10.1016/j.bmc.2010.05.001] |
| 41. Prado-Prado FJ, García-Mera X, González-Díaz H.. (2010) Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species., 18 (6): [PMID:20185316] [10.1016/j.bmc.2010.01.068] |
| 42. Gozalbes R, Pineda-Lucena A.. (2010) QSAR-based solubility model for drug-like compounds., 18 (19): [PMID:20810286] [10.1016/j.bmc.2010.08.003] |
| 43. Yoon HC, Choi E, Park JE, Cho M, Seo JJ, Oh SJ, Kang JS, Kim HM, Park SK, Lee K, Han G.. (2010) Property based optimization of δ-lactam HDAC inhibitors for metabolic stability., 20 (22): [PMID:20850971] [10.1016/j.bmcl.2010.08.117] |
| 44. PubChem BioAssay data set, |
| 45. PubChem BioAssay data set, |
| 46. PubChem BioAssay data set, |
| 47. PubChem BioAssay data set, |
| 48. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 49. Chen T, Benmohamed R, Arvanites AC, Ralay Ranaivo H, Morimoto RI, Ferrante RJ, Watterson DM, Kirsch DR, Silverman RB.. (2011) Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis., 19 (1): [PMID:21095130] [10.1016/j.bmc.2010.10.052] |
| 50. Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.. (2011) Prediction of drug intestinal absorption by new linear and non-linear QSPR., 46 (1): [PMID:21112128] [10.1016/j.ejmech.2010.11.005] |
| 51. Choi E, Lee C, Park JE, Seo JJ, Cho M, Kang JS, Kim HM, Park SK, Lee K, Han G.. (2011) Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors., 21 (4): [PMID:21256006] [10.1016/j.bmcl.2010.12.079] |
| 52. Wlodarczyk N, Le Broc-Ryckewaert D, Gilleron P, Lemoine A, Farce A, Chavatte P, Dubois J, Pommery N, Hénichart JP, Furman C, Millet R.. (2011) Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer., 54 (5): [PMID:21299244] [10.1021/jm101067y] |
| 53. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 54. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 55. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 56. Matthews EJ, Kruhlak NL, Weaver JL, Benz RD, Contrera JF.. (2004) Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling., 1 (4): [PMID:16472241] [10.2174/1570163043334794] |
| 57. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.. (2010) Membrane transporters in drug development., 9 (3): [PMID:20190787] [10.1038/nrd3028] |
| 58. Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.. (2011) QSAR-based permeability model for drug-like compounds., 19 (8): [PMID:21458999] [10.1016/j.bmc.2011.03.011] |
| 59. PubChem BioAssay data set, |
| 60. PubChem BioAssay data set, |
| 61. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS.. (2001) Rational use of in vitro P-glycoprotein assays in drug discovery., 299 (2): [PMID:11602674] |
| 62. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 63. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 64. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 65. Nandhikonda P, Lynt WZ, McCallum MM, Ara T, Baranowski AM, Yuan NY, Pearson D, Bikle DD, Guy RK, Arnold LA.. (2012) Discovery of the first irreversible small molecule inhibitors of the interaction between the vitamin D receptor and coactivators., 55 (10): [PMID:22563729] [10.1021/jm300460c] |
| 66. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.. (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., 25 (10): [PMID:22931300] [10.1021/tx300075j] |
| 67. (1994) TP-search Transporter Database, 479 (1): |
| 68. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 69. Troutman MD, Thakker DR.. (2003) Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium., 20 (1): [PMID:12948019] [10.1023/a:1025001131513] |
| 70. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y.. (2005) Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists., 316 (1): [PMID:16291876] [10.1124/jpet.105.094052] |
| 71. Bednarczyk D, Ekins S, Wikel JH, Wright SH.. (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1., 63 (1): [PMID:12606755] [10.1124/mol.63.3.489] |
| 72. Faassen F, Vogel G, Spanings H, Vromans H.. (2003) Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs., 263 (1): [PMID:12954186] [10.1016/s0378-5173(03)00372-7] |
| 73. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE.. (2000) Influence of passive permeability on apparent P-glycoprotein kinetics., 17 (1): [PMID:11303953] [10.1023/a:1007692622216] |
| 74. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
| 75. Xia Y, Choi HK, Lee K.. (2012) Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors., 49 [PMID:22305612] [10.1016/j.ejmech.2012.01.033] |
| 76. Akamatsu M.. (2011) Importance of physicochemical properties for the design of new pesticides., 59 (7): [PMID:20879794] [10.1021/jf102525e] |
| 77. Hough L, Nalwalk J, Menge W, Leurs R, Timmerman H. (2004) Improgan-like Analgesics: A Family of Compounds Derived From Histamine Anatgonists, 13 (1): [10.1007/s00044-004-0012-z] |
| 78. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.. (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling., 56 (3): [PMID:23241029] [10.1021/jm301302s] |
| 79. Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Börjesson L, Gustavsson L.. (2013) Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2., 56 (18): [PMID:23984907] [10.1021/jm400966v] |
| 80. Unpublished dataset, |
| 81. Unpublished dataset, |
| 82. Unpublished dataset, |
| 83. Settimo L, Bellman K, Knegtel RM.. (2013) Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds., [PMID:24249037] [10.1007/s11095-013-1232-z] |
| 84. Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, Nandhikonda P, Cook JM, Singh RK, Bikle DD, Arnold LA.. (2014) Development of novel Vitamin D Receptor-Coactivator Inhibitors., 5 (2): [PMID:24799995] [10.1021/ml400462j] |
| 85. Cinelli MA, Li H, Chreifi G, Martásek P, Roman LJ, Poulos TL, Silverman RB.. (2014) Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition., 57 (4): [PMID:24472039] [10.1021/jm401838x] |
| 86. Mohammad H, Mayhoub AS, Ghafoor A, Soofi M, Alajlouni RA, Cushman M, Seleem MN.. (2014) Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus., 57 (4): [PMID:24387054] [10.1021/jm401905m] |
| 87. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 88. PubChem BioAssay data set, |
| 89. PubChem BioAssay data set, |
| 90. Mateus A, Matsson P, Artursson P.. (2014) A high-throughput cell-based method to predict the unbound drug fraction in the brain., 57 (7): [PMID:24601604] [10.1021/jm401963n] |
| 91. Khanfar MA, Quinti L, Wang H, Choi SH, Kazantsev AG, Silverman RB.. (2014) Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors., 76 [PMID:24602787] [10.1016/j.ejmech.2014.02.003] |
| 92. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds, [10.6019/CHEMBL3301361] |
| 93. Boland S, Alen J, Bourin A, Castermans K, Boumans N, Panitti L, Vanormelingen J, Leysen D, Defert O.. (2014) Novel Roflumilast analogs as soft PDE4 inhibitors., 24 (18): [PMID:25149511] [10.1016/j.bmcl.2014.07.016] |
| 94. Liu Y, Li F, Wu L, Wang W, Zhu H, Zhang Q, Zhou H, Yan B.. (2015) Improving both aqueous solubility and anti-cancer activity by assessing progressive lead optimization libraries., 25 (9): [PMID:25827524] [10.1016/j.bmcl.2015.03.016] |
| 95. Mukherjee P, Li H, Sevrioukova I, Chreifi G, Martásek P, Roman LJ, Poulos TL, Silverman RB.. (2015) Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase., 58 (3): [PMID:25489882] [10.1021/jm501719e] |
| 96. Papadopoulou MV, Bloomer WD, Lepesheva GI, Rosenzweig HS, Kaiser M, Aguilera-Venegas B, Wilkinson SR, Chatelain E, Ioset JR.. (2015) Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents., 58 (3): [PMID:25580906] [10.1021/jm5015742] |
| 97. Dawson S, Stahl S, Paul N, Barber J, Kenna JG.. (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans., 40 (1): [PMID:21965623] [10.1124/dmd.111.040758] |
| 98. Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.. (2013) Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors., 41 (1): [PMID:23033255] [10.1124/dmd.112.048264] |
| 99. Grime K, Paine SW.. (2013) Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement., 41 (2): [PMID:23139379] [10.1124/dmd.112.049312] |
| 100. PubChem BioAssay data set, |
| 101. Davis DC, Mohammad H, Kyei-Baffour K, Younis W, Creemer CN, Seleem MN, Dai M.. (2015) Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus., 101 [PMID:26164843] [10.1016/j.ejmech.2015.06.031] |
| 102. WHO Anatomical Therapeutic Chemical Classification, |
| 103. Open TG-GATES, [10.6019/CHEMBL3885861] |
| 104. DrugMatrix, [10.6019/CHEMBL3885881] |
| 105. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 106. Unpublished dataset, |
| 107. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 108. Hammad A, Abutaleb NS, Elsebaei MM, Norvil AB, Alswah M, Ali AO, Abdel-Aleem JA, Alattar A, Bayoumi SA, Gowher H, Seleem MN, Mayhoub AS.. (2019) From Phenylthiazoles to Phenylpyrazoles: Broadening the Antibacterial Spectrum toward Carbapenem-Resistant Bacteria., 62 (17): [PMID:31369262] [10.1021/acs.jmedchem.9b00720] |
| 109. (2012) Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs, |
| 110. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 111. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 112. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
| 113. Mezeiova E, Janockova J, Andrys R, Soukup O, Kobrlova T, Muckova L, Pejchal J, Simunkova M, Handl J, Micankova P, Capek J, Rousar T, Hrabinova M, Nepovimova E, Marco-Contelles JL, Valko M, Korabecny J.. (2021) 2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease., 211 [PMID:33360800] [10.1016/j.ejmech.2020.113112] |
| 114. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
| 115. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL.. (2019) Mapping human microbiome drug metabolism by gut bacteria and their genes., 570 (7762): [PMID:31158845] [10.1038/s41586-019-1291-3] |
